AzTrials
AzTrials

Advanced Solid TumorsPhase 2NCT05541822

To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation

A Phase 2 study testing Vabametkib and Lazertinib in people with Advanced Solid Tumors, run by Abion Inc at 24 sites in 3 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Advanced Solid Tumors
What is being tested?
Vabametkib and Lazertinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
178 participants
Where
24 sitesin 3 countries
Study dates
17 Jan 2023to Feb 2029
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female ≥ 18 years of age or designated age of majority according to the regulatory authorities, whichever is higher.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS), 0 or 1.
  • Have a life expectancy of at least 3 months.
  • Diagnosis:
  • must have histologically or cytologically confirmed NSCLC, advanced, recurrent, or metastatic,
  • For Cohort 1: MET exon 14 skipping suspected by local or central biomarker assessment. [local testing is accepted for eligibility; all patients will have confirmation by central laboratory, but this result is not necessary for eligibility; local molecular pathology result will suffice]. This testing can be from archival or fresh tissue sample and/or blood specimen; any sample, any test positive subjects are eligible.
Show all 37Show fewer
  • For Cohort 2:
  • Non-squamous histology (confirmed by histology or cytology)
  • EGFR mutation-positive including exon 19 deletions or exon 21 L858R as detected by an FDA-approved or other validated test in a CLIA certified laboratory (sites in the US) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care. (Note: A copy of the test report documenting the EGFR mutation must be included in the participant records and it must be reviewed by the Medical monitor.)
  • Radiological documentation of disease progression while on continuous treatment with the 1st line 3rd generation EGFR-TKI
  • Prior objective clinical benefit defined by either partial or complete radiological response, or durable SD (SD should last > 6 months) from the 1st line 3rd generation EGFR-TKI
  • Interval between documentation of radiological progression of disease on the 1st line 3rd generation EGFR TKI and first dose of study drug should be ≤ 60 days
  • MET amplification or overexpression from tumor sample collected following progression on 1st line 3rd generation EGFR-TKI • Amplification GCN ≥ 10 indicated by FISH (confirmed centrally, slides or image from local laboratory will be confirmed by the central pathologist) or NGS (confirmed either centrally or locally) • Overexpression indicated by IHC90+ (i.e. 3+ staining in ≥ 90% tumor cells by central test, if local IHC results are available, image from local laboratory will be confirmed by central pathologist. Despite the image submission, tissue unstained slides should be sent to central laboratory for confirmation of MET amplification or overexpression.)
  • Treatment experience
  • Cohort 1: Anti-tumor treatment naïve subject upon refusal to receive 1st line standard of care, or not tolerated to 1st line standard of care, or progressed after standard of care with no greater than 2 prior treatment regimens (neoadjuvant, adjuvant, and maintenance therapies do not qualify as separate treatment regimens).
  • Cohort 2: Progressed on prior the 1st line 3rd generation EGFR-TKI for the treatment of advanced/metastatic NSCLC
  • At least one measurable lesion per response evaluation criteria in solid tumors (RECIST) 1.1
  • While on study treatment and for 6 months after the last dose of study treatment, a patient must:
  • Not breast feed or be pregnant.
  • Not donate gametes (ie, eggs or sperm) or freeze for future use for the purpose of assisted reproduction.
  • Wear an external condom when engaging in any activity that allows for passage of ejaculate to another person.
  • If of childbearing potential
  • Have a negative highly sensitive (eg, beta-human chorionic gonadotropin [β-hCG]) pregnancy test at screening and within 72 hours before the first dose of study treatment, and agree to further pregnancy tests, ii. Practice at least 1 highly effective method of contraception; if oral contraceptives are used, a barrier method of contraception must also be used.
  • If a patient's partner is of childbearing potential, the participant must use a condom and partner of the participant must also be practicing a highly effective method of contraception. A vasectomized patient must still use a condom, but the partner is not required to use contraception.
  • Resolution of prior-therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 per CTCAE v 5.0, and no treatment for these AEs for at least 2 weeks prior to the time of enrollment. Alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 AEs not constituting a safety risk based on investigator's judgment are acceptable.
  • Adequate organ function as indicated by laboratory values.
  • Submit tissue and blood specimens.
  • <!-- -->
  • Cohort 1:
  • All patients should submit tumor tissue/block collected from fresh biopsy or have available archival formalin-fixed, paraffin-embedded tumor tissue specimen. The archival tissue must be:
  • collected after progression from most recent prior systemic anti-cancer treatment, OR
  • If an archival tissue collected after progression to the most recent systemic anti-cancer treatment is not available, tissue samples from previous lines of treatment are acceptable.
  • For fresh biopsied sample, core needle biopsy is permitted. Samples from fine-needle aspiration (FNA) is not acceptable unless the result of MET exon 14 skipping from local testing is available.
  • All patients must submit blood samples.
  • Cohort 2:
  • All patients should submit either fresh or archival tumor slides/block collected after progression from 1st line 3rd generation EGFR TKI. The archival tissue can be permitted ONLY IF it is collected after progression from 1st line 3rd generation EGFR TKI.
  • All patients should submit blood samples. 11. Able and willing to comply with the protocol and the restrictions and assessments therein.

Who cannot join

  • Previous severe hypersensitivity reaction to any component of study drug(s).
  • Prior therapy
  • Previous treatment with c-MET inhibitors or hepatocyte growth factor (HGF)-targeting therapy.
  • For Cohort 2, prior chemotherapy for advanced, recurrent, or metastatic setting.
  • Genetic analysis results:
  • Cohort 1: Existing genetic data from the patient's tumor tissue showing known molecular alterations which would make them eligible for targeted therapies (e.g., EGFR mutations, ALK rearrangements, KRAS mutation, ROS1 translocation, BRAF mutation, RET alteration, and NTRK fusion, etc.).
Show all 43Show fewer
  • Cohort 2: Patients with known molecular alterations that can't benefit from study medication (e.g., EGFR mutation known to be associated with the resistance to 3rd generation EGFR TKIs, such as C797X or insertion 20, ALK rearrangements, KRAS mutation, ROS1 translocation, BRAF mutation, RET alteration, and NTRK fusion, etc.).
  • Chronic inflammatory liver condition. History or clinical evidence of any significant liver or biliary pathology including cirrhosis, infectious disease, inflammatory conditions, steatosis, or cholangitis (including ascending cholangitis, primary sclerosing cholangitis, obstruction, perforation, fistula of biliary tract, spasm of sphincter of Oddi, biliary cyst or biliary atresia).
  • Past medical history of Interstitial Lung Disease (ILD)/pneumonitis, drug-induced or radiation ILD/pneumonitis that required steroid treatment or other immune suppressive agents, or evidence of current symptomatic interstitial lung disease or unexplained pulmonary symptoms indicative of ILD such dyspnea, cough, or fever.
  • Impairment of Gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drugs (e.g., ulcerative diseases, uncontrolled nausea, uncontrolled vomiting, uncontrolled diarrhea, or malabsorption syndrome)
  • Prior organ or stem cell transplant.
  • Known active infection with human immunodeficiency virus (HIV), human T-cell leukemia virus, type (HTLV-1), hepatitis B virus (HBV), or hepatitis C virus (HCV), unless the patients fall into below categories (patients fall into one of the a, b, c category are eligible to participate)
  • HIV
  • ✓ CD4+ cells ≥ 350 cells/µL
  • ✓ No history of AIDS
  • ✓ No history of opportunistic infection in the past 12 months
  • HCV
  • ✓ Undetectable viral load (Participants positive for hepatitis C antibody are eligible only if polymerase chain reaction is negative for hepatitis C RNA)
  • HBV ✓ Concurrent HBV treatment and undetectable viral load (Participants with a past or resolved hepatitis B infection defined as the presence of hepatitis B core antibody [anti-HBc] and absence of hepatitis B surface antigen are eligible)
  • Symptomatic ascites or pleural effusion, unless clinically stable for at least two weeks following treatment for these conditions (including therapeutic thoraco- or paracentesis).
  • Known active central nervous system (CNS) primary tumor or metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks prior to first dose of study medication(s), have no evidence of new or enlarging brain metastases and are off steroids for at least 15 days prior to first dose of study medication(s).
  • Presence or history of a malignant disease other than disease to be treated in current protocol that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, indolent malignancies that currently do not require treatment, and completely resected carcinoma in situ of any type.
  • Active infection requiring therapy. However, subject with minor infections requiring oral antibiotics, (e.g., urinary tract infection, Upper respiratory tract infection, etc.) could be eligible based on investigator's judgement.
  • Use of systemic corticosteroids > 10 mg/day prednisone or equivalent within 30 days or other immunosuppressive drugs within 30 days prior to first drug administration.
  • Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued specified period prior to the start of treatment with study drug and for the duration of the study.
  • For Vabametkib (Wash-out: 1 week)
  • Strong and moderate inhibitors/inducers of P-glycoprotein
  • Strong and moderate inhibitors/inducers of CYP3A4
  • Proton pump inhibitors (PPI)
  • Potassium-competitive acid blockers For Lazertinib
  • Strong and moderate CYP3A4 inducers
  • Medications possibly prolong QT interval or induce Torsades de Pointes
  • Has received or will receive a live vaccine within 30 days prior to the first administration of study medication. Seasonal flu vaccine that does not contain live vaccine are permitted.
  • Received an investigational product (except for EGFR TKI in Cohort 2) or treated with an investigational device within 30 days prior to first study drug administration.
  • Has been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors (except for EGFR TKI in Cohort 2) within 2 weeks (4 weeks in case of thoracic radiotherapy to lung fields) or 5 half-lives (whichever is longer) of the start of study treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of study treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of study treatment; 7-day washout is permitted for palliative radiation (i.e. limited field, ≤ 14-day course of radiotherapy) to non-CNS lesions.
  • History or clinical evidence of any surgical or medical condition which the investigator judges as likely to interfere with the results of the study or pose an additional risk in participating e.g., rapidly progressive or uncontrolled disease involving a major organ system-vascular, ophthalmologic, cardiac (clinically important abnormalities in rhythm, conduction or morphology of resting ECG, uncontrolled hypertension, uncontrolled symptomatic heart failure), pulmonary, gastrointestinal, gynecologic, hematologic, neurologic, neoplastic, renal, endocrine, autoimmune or an immunodeficiency, or clinically significant active psychiatric or abuse disorders.
  • Is a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
  • Patients with a corrected QT interval (using Fridericia's correction formula) (QTcF) of > 470 msec.
  • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first degree relatives or any concomitant medications known to prolong QT interval or induce Torsades de Pointes.
  • Congestive heart failure (CHF), defined as New York Heart Association (NYHA) class III-IV or hospitalization for CHF (any NYHA class), within 6 months of randomization.
  • An active or past medical history of pericarditis, pericardial effusion that is clinically unstable, or myocarditis. Pericardial effusion considered due to the disease under study is permitted if clinically stable at Screening.
  • (for Cohort 2) Baseline LVEF either <50% or below the lower limit of normal (LLN) per institutional guidelines, as assessed by screening echocardiogram or MUGA scan.
  • (for Cohort 2) Patients who have been receiving medications with potential for QT interval prolongation will be eligible only when the wash out period was finished.

Trial locations and contacts

24 sites in 3 countries. Contact the study team or a site near you to ask about taking part.

24 sites in 3 countries

South Korea14 sites, 14 recruiting
  • Chungbuk National University Hospital

    Cheongju-si, 28645

    Ki Hyeong Lee, 82-43-269-6015, kihlee@chungbuk.ac.kr

    Inyoung Jeong, 82-10-5579-7261, jeonginyoung22@gmail.com

    Recruiting
  • Boramae Medical Center

    Dongjak, Seoul, 07061

    Jin-Soo Kim, 82-2-870-3875, gistmd@gmail.com

    Youahn Seo, 82-2-870-3875, uahn57@naver.com

    Recruiting
  • National Cancer Center

    Goyang-si, Gyeonggi-do, 10408

    Ji-Youn Han, +82319201154, jymama@ncc.re.kr

    Ji Won Yoo, 82-10-5620-5953, jiwonyoo@ncc.re.kr

    Recruiting
  • Gachon University Gil Medical Center

    Incheon, 21565

    Young Saing Kim, +82-10-3475-2435, zoomboom@gilhospital.com

    Hyerim Choi, +82-10-9930-7579, jasmin993075@naver.com

    Recruiting
  • Gyeongsang National University Hospital

    Jinju, 52728

    Gyeong-won Lee, +82-55-750-9454, brightree24@gmail.com

    Soon Ha Kim, 82-10-9079-8069, soonha109@naver.com

    Recruiting
  • Seoul National University Bundang Hospital

    Seongnam-si, 13620

    Yu Jung Kim, +82-31-787-7041, cong1005@gmail.com

    Bora Yoon, +82-10-2351-0197, purplegirl33@naver.com

    Recruiting
  • Korea University Anam Hospital

    Seoul, Seoul, 02841

    Yoon Ji Choi, 82-2-920-6079, yj_choi@korea.ac.kr

    Woo-seon Lim, 82-2-920-6079, happyseony@kumc.or.kr

    Recruiting
  • Kangbuk Samsung Hospital

    Seoul, 03181

    Yun-Gyoo Lee, 82-2-2001-1859, yungyoolee@gmail.com

    Nara Shin, 82-10-6788-3022, snr150604@daum.net

    Recruiting
  • Asan Medical Center

    Seoul, 05505

    Daeho Lee, +82230103214, leedaeho@amc.seoul.kr

    Hajin Lee, 82-10-4692-2292, a01046922292@gmail.com

    Recruiting
  • Samsung Medical Center

    Seoul, 06351

    Se-hoon Lee, +82234101132, sehoon.lee@samsung.com

    SooJung Lee, +82-10-8906-9965, sj62.lee@samsung.com

    Recruiting
  • The Catholic University of Korea, Seoul St Mary's Hospitals

    Seoul, 06591

    Jin-Hyoung Kang, +82225613238, oncologykang@naver.com

    Joo Yeon Kim, 82-10-3537-3359, jyn1023@naver.com

    Recruiting
  • Severance Hospital

    Sinchon-dong, Seoul, 03776

    Hye Ryun Kim, 82-2-2228-8173, nobelg@yuhs.ac

    Bo Hyun An, 82-2-2228-8173, scbha@yuhs.ac

    Recruiting
  • Ajou University Hospital

    Suwon, Gyeonggi-do, 16499

    Yong Won Choi, 82-31-219-4267, dreamliebe@hanmail.net

    Yerim Jung, 82-10-2465-5345, 114907@aumc.ac.kr

    Recruiting
  • The Catholic University of Korea St Vincents Hospital

    Suwon, 16248

    Byoung-Yong Shim, +82-31-249-8455, shimby@catholic.ac.kr

    Yunhwa Kim, 82-10- 2953- 5676, xxx1205xxx@naver.com

    Recruiting

Other trials in South Korea

Taiwan6 sites, 6 recruiting
  • China Medical University Hospital

    Taichung, 404

    Te-Chun Hsia, +886 4-22065866, d1914@mail.cmuh.org.tw

    Shu Yin Liao, +886-972-723899, asd911102@yahoo.com.tw

    Recruiting
  • National Cheng Kung University Hospital

    Tainan, 704

    Chun-Hui Lee, +886 972-401657 ext. 3042, chunhui811012@gmail.com

    Pei-Hsuan Lin, +886-6-2353535 ext. 3042, linpei1029@gmail.com

    Recruiting
  • Chi Mei Hospital, Liouying

    Tainan, 736

    Shang-Wen Chen, +886 6-6226999 ext. 73232, saintwin.chen@gmail.com

    Olivia Chen, +886-6-6226999 ext. 73232, hospital77649@gmail.com

    Recruiting
  • National Taiwan University Cancer Center (NTUCC)

    Taipei, 10052

    Yang Chih-Hsin, +886-2-23123456 ext. 67855, chihyang@ntu.edu.tw

    Ya-Ying Bai, +886-2-23123456 ext. 67855, yaying0508@ntuh.gov.tw

    Recruiting
  • National Taiwan University Hospital

    Taipei, 100

    Chih-Hsin Yang, +886 2-23123456 ext. 67511, chihyang@ntu.edu.tw

    Ya-Ying Bai, +886-2-23123456 ext. 67855, yaying0508@ntuh.gov.tw

    Recruiting
  • Taipei Veterans General Hospital

    Taipei, 112

    Yuh-Min Chen, +886 2-28757865, ymchen@vghtpe.gov.tw

    Yu-Ching Fang, +886-2-28712121 ext. 82872, fangyaixian0928@gmail.com

    Recruiting

Other trials in Taiwan

United States4 sites, 4 recruiting
  • The Henry Ford Cancer Institute

    Detroit, Michigan, 48202

    Not yet recruiting
  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030-4000

    Le Xiuning, (713) 561-2486, XLe1@mdanderson.org

    Patti Smithwick, (713) 561-2486, pjsmithwick@mdanderson.org

    Recruiting
  • Cancer Care of North Florida, PA (Lake City Cancer Care, LLC) - Medical Oncology

    Lake City, Florida, 32024-3456

    Waseemulla Khan, (386) 755-1655, wkhan@cancercareofnorthflorida.com

    Lilibeth Macias, (386) 755-1655 ext. 6200, LMacias@cancercareofnorthflorida.com

    Recruiting
  • Mid Florida Center

    Orange City, Florida, 32763-8316

    Santosh Nair, (386) 538-3169, drsmnair@aorcorp.com

    Kiran Penta, (386) 538-3169, kiran@aorcorp.com

    Recruiting

Other trials in United States

About this study

Official title: A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation

ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of advance solid tumors with c-MET alterations as monotherapy.

Read the detailed description

This study will start with one cohort and it will be a parallel cohort expansion study.

Being tested
Vabametkib, Lazertinib
Keywords
c-MET

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VabametkibDrug

    Tablets

    Route of Administration: Oral

  • LazertinibDrug

    Tablets

    Route of Administration: Oral

Study groups in NCT05541822
Study groupRoleWhat they receive
Cohort 1: VabametkibExperimentalSubjects will receive vabametkib 800 mg, monotherapy, administered orally once daily in 21-day cycles
Receives: Drug: Vabametkib
Cohort 2: Lazertinib & VabametkibExperimentalPart 1 (Safety Run-in): Subjects will receive lazertinib 240 mg in combination with one of three assigned dose levels of vabametkib, administered orally once daily in 21-day cycles Part 2 (Random Dose Optimization): A maximum of two vabametkib dose levels will be evaluated in this part. Patients will be randomized in 1:1 ratio to vabametkib dose level 1 (selected from Part 1) plus the determined dose of lazertinib or dose level 2 (selected from Part 1) plus the determined dose of lazertinib Part 3 (Randomized Clinical Trial): Patients will be randomized in 1:1 ratio to optimized vabametkib dose (selected from Part 2) plus lazertinib or Standard of Care (SOC) arm. SOC arm will be decided by the time of Part 3 initiation
Receives: Drug: Vabametkib; Drug: Lazertinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Cohort 1: Objective response rate (ORR) according to response evaluation criteria in solid tumors (RECIST)1.1 by Blinded Independent Central Review (BICR)

    ORR is defined as the proportion of patients who experience a complete response (CR) or partial response (PR) as measured by RECIST 1.1

    Measured: Up to 12 months

  2. Cohort 2 Part 1: Incidence of DLT (Dose Limiting Toxicity)

    Measured: Up to 12 months

  3. Cohort 2 Part 2: Optimal dose of vabametkib and lazertinib combination for Part 3 based on the risk-benefit assessment considering both ORR (Objective Response Rate) and AE (Adverse Events)

    Measured: Up to 12 months

  4. Cohort 2 Part 3: ORR (Objective Response Rate)

    Measured: Up to 12 months

Secondary outcomes (43)
  1. Cohorts 1 & 2: Objective response rate (ORR) measured by RECIST 1.1 by BICR

    ORR is defined as the proportion of patients who experience a CR or PR as measured by RECIST 1.1 by BICR

    Measured: Up to 12 months

  2. Cohorts 1 & 2: Duration of response (DoR) as measured by RECIST 1.1 by BICR

    DoR as measured by RECIST 1.1 by ICR and investigator will be used. DoR is defined as the time period from documentation of disease response to disease progression.

    Measured: Up to 12 months

  3. Cohorts 1 & 2: Disease advanced control rate (DCR) as measured per RECIST 1.1 by BICR

    DCR is defined as the proportion of patients who achieve CR, PR, and stable disease (SD) as measured per RECIST 1.1 by ICR and investigator

    Measured: Week 12

  4. Cohorts 1 & 2: Progression-free survival (PFS) according to RECIST 1.1 by BICR

    PFS defined as the time from first dose of vabametkib until disease progression according to RECIST 1.1 by investigator

    Measured: Up to 18 months

  5. Cohorts 1 & 2: Overall survival (OS) according to RECIST 1.1

    OS defined as the time from first dose of study drug until death from any cause

    Measured: Up to 18 months

  6. Cohort 1: Incidence of AEs of vabametkib

    Safety and tolerability will be a comprehensive evaluation of AEs based on:

    • Incidence of AEs (including grade 3 and 4 TEAEs)
    • Vital signs measurements
    • Clinical laboratory analyses
    • ECGs
    • Physical examination findings
    • Visual examinations
    • Concomitant medications monitored throughout the study

    Measured: Up to 12 months

  7. Cohort 2: Incidence of AEs of vabametkib with lazertinib combination

    Safety and tolerability will be a comprehensive evaluation of AEs based on:

    • Incidence of AEs (including grade 3 and 4 TEAEs)
    • Vital signs measurements
    • Clinical laboratory analyses
    • ECGs (electrocardiogram)
    • ECHO (Echocardiography) or MUGA (Multiple Gated Acquisition) scans
    • Physical examination findings
    • Visual examinations
    • Concomitant medications monitored throughout the study

    Measured: Up to 12 months

  8. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Tmax: Time to reach maximum concentration

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  9. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Tmax: Time to reach maximum concentration

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  10. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cmax: Maximum concentration

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  11. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cmax: Maximum concentration

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  12. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Ke: apparent first-order terminal elimination rate constant

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  13. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Ke: apparent first-order terminal elimination rate constant

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  14. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - T1/2: apparent first-order terminal elimination half-life

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  15. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - T1/2: apparent first-order terminal elimination half-life

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  16. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-t: area under the concentration-time curve from time zero to the last measurable concentration

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  17. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-t: area under the concentration-time curve from time zero to the last measurable concentration

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  18. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-12: area under the concentration-time curve from time zero to 12 hr post-dose

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  19. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-12: area under the concentration-time curve from time zero to 12 hr post-dose

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  20. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-24: area under the concentration-time curve from time zero to 24 hr post-dose

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  21. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-24: area under the concentration-time curve from time zero to 24 hr post-dose

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  22. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-tau: area under the plasma concentration-time curve from time zero to next dosing

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  23. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-tau: area under the plasma concentration-time curve from time zero to next dosing

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  24. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-∞: area under the plasma concentration-time curve from time zero to infinity

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  25. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - AUC0-∞: area under the plasma concentration-time curve from time zero to infinity

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  26. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - %Extrap: percentage of AUC0-∞ obtained by extrapolation

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  27. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - %Extrap: percentage of AUC0-∞ obtained by extrapolation

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  28. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cave: average concentration over a dosage interval

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  29. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cave: average concentration over a dosage interval

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  30. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - FLUCP: fluctuation over a dosage interval

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  31. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - FLUCP: fluctuation over a dosage interval

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  32. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - R: accumulation ratio

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  33. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - R: accumulation ratio

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  34. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - CL/F: apparent systemic clearance

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  35. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - CL/F: apparent systemic clearance

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  36. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Vss/F: apparent volume of distribution at steady-state

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  37. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Vss/F: apparent volume of distribution at steady-state

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  38. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Vz/F: apparent volume of distribution

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  39. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Vz/F: apparent volume of distribution

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  40. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cmin: minimum concentration during dosage interval

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  41. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Cmin: minimum concentration during dosage interval

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  42. Cohorts 1 & 2: Intensive Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Ctrough: concentration of the drug just prior to administration of next dosage

    Measured: Cycle 1: Days 1, 2, 15, and 16 (pre-dose). Pre-dose on Day 1 from Cycle 2 Day 1 onward until disease progression (PD), or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

  43. Cohorts 1 & 2: Sparse Sampling - Pharmacokinetic (PK) parameter from plasma vabametkib concentration - Ctrough: concentration of the drug just prior to administration of next dosage

    Measured: Cycle 1: Day 1, Even cycles: Day 1 until disease progression (PD) or discontinuation of treatment for any other reason. Each cycle is 21 days (Up to approximately 6 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Sep 2022
  2. Study start17 Jan 2023
  3. Primary completionFeb 2029 (estimated)
  4. Study completionFeb 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
178 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05541822
Sponsor's protocol ID
ABN401-003
Status last verified
May 2025
First submitted
4 Sep 2022
Last updated
22 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Kim DK, Park JW, Cho HB, Choi SJ, Lee SS, Kim Y, Lee JB, Lim SM, Yu MR, Cho BC. Synergistic Antitumor Activity of Combination Therapy with a MET TKI Vabametkib and a Third-Generation EGFR TKI Lazertinib in MET-Amplified EGFR-Mutant NSCLC. Cancer Res Treat. 2026 Mar 31. doi: 10.4143/crt.2025.1399. Online ahead of print.

    PubMed 41927036

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Vabametkib and Lazertinib in people with Advanced Solid Tumors, run by Abion Inc at 24 sites in 3 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 37 inclusion and 43 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 22 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 24 sites in South Korea, Taiwan, United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Viki Kim (82-2-6006-4767, viki.kim@abionbio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Cohort 1: Objective response rate (ORR) according to response evaluation criteria in solid tumors (RECIST)1.1 by Blinded Independent Central Review (BICR) (time frame: Up to 12 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05541822, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in